Immunotherapies are transforming conventional cancer treatments with significant improvement of patient survival rates. FDA-approved immunotherapies (immune checkpoint inhibitors, ICIs) have shown remarkable success in the treatment of hematologic malignancies but very low response rate in patients with solid tumors. Therefore, there is an urgent need for novel therapies against solid malignancies. Cura Therapeutics is developing […]
Read More